Pembrolizumab plus radiation before surgery for rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving pembrolizumab (an immunotherapy medicine) together with short-course radiation before surgery helps people with localized rectal cancer. It is mainly for tumors that are microsatellite stable (MSS).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older, and your rectal cancer was confirmed by biopsy.
- Your cancer is localized rectal adenocarcinoma (not spread to distant organs), in a specific TNM stage group.
- Your tumor is microsatellite stable (MSS), not MSI-high.
- Your overall health is good enough for treatment (ECOG 0–1).
- A tumor board recommends short-course radiation plus surgery before treatment begins.
- You can provide tumor tissue that has not had radiation before (archived block or a fresh biopsy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a shorter course of radiation that avoids draining lymph nodes, followed by an immunotherapy drug (PD-1 inhibitor), for people with stage II or III rectal cancer that is mismatch repair proficient (pMMR) or microsatellite stable (MSS). The goal is to see if this approach can shrink tumors while keeping lymph nodes intact.
This trial tests a combination of radiation therapy, chemotherapy, and immunotherapy given before surgery for rectal cancer that has high-risk features. The goal is to shrink the tumor and improve outcomes for patients with this aggressive form of cancer.
This study tests whether combining mFOLFOX6 chemotherapy with an immunotherapy drug (anti-PD-1) before surgery can shrink locally advanced rectal cancer. It is open to people whose tumors are mismatch repair proficient (pMMR) or microsatellite stable (MSS).
This trial tests a combination of short-course radiation, chemotherapy, and two types of immunotherapy (HLX07 and Serplulimab) before surgery for advanced rectal cancer. It aims to see if this approach helps shrink tumors and improve outcomes.
This trial tests a combination of a PD-L1 inhibitor (adebrelimab), short-course radiation, and chemotherapy given before surgery for locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial studies giving long-course radiation and chemotherapy before surgery, plus an immunotherapy medicine (PD-1) to help the tumor shrink more. It’s for people with stage II or III rectal cancer that has not spread to distant organs.
Hear when a new Rectum Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.